

# FOCUS ON VALUE




## Prevalence of Cataract Surgery in the U.S.

**4.3** Million surgeries performed annually<sup>1</sup>

**3.1%** Compounded annual growth rate<sup>1</sup>

**92%** Of patients are implanted with monofocal or monofocal toric IOLs<sup>2</sup>

## Cataract surgery patients are younger in many U.S. communities<sup>3\*</sup>



\*Geographic age range differences of 1st eye cataract surgery

## Cataract patients participate in a variety of activities using vision at distance, intermediate and near



Patients **55 years and older** spend a substantial amount of time for leisure and sports activities<sup>4</sup>

### Daily time spent on leisure and sports activities by U.S. residents<sup>4\*</sup>



55-64 Years



65-74 Years




75+ Years


\* Leisure and sports activities included exercise, recreation, socializing and communicating, watching TV, playing games, using a computer for personal interest, playing or listening to music, and attending arts, cultural, and entertainment events. Figure excludes sleeping and personal care activities.

# TECNIS Eyhance™ IOLs and TECNIS Eyhance™ Toric II IOLs leverage the strength of the proven TECNIS® platform to deliver high-quality vision

85% of the surface of the **TECNIS Eyhance™** is identical to the TECNIS® 1-Piece IOL<sup>5</sup>



The modified anterior surface of the TECNIS Eyhance™ IOL creates a small continuous increase in central lens power<sup>6\*</sup>



\* The safety and effectiveness of the TECNIS Eyhance™ IOL has not been substantiated in clinical trials. The effects of the TECNIS Eyhance™ IOL optical design on quality of vision, contrast sensitivity, and subjective visual disturbances have not been evaluated clinically.  
 \*\*Clinically meaningful extension of depth of focus of TECNIS Eyhance™ IOL has not been demonstrated in clinical trials.

## TECNIS Eyhance™ IOLs and TECNIS Eyhance™ Toric II IOLs deliver **top IOL features rated by ophthalmologists<sup>10</sup>**



Toric Optics



Clarity of Optics



Aspheric Optics

### Feature

### Benefit

Spherical aberration corrected to essentially zero due to wavefront-designed optic



Provides sharp quality of vision<sup>11</sup>

Low induction of chromatic aberration due to its material



Provides high image contrast performance under all lighting conditions<sup>12</sup>

Less capsular phimosis observed




Minimizes decreased vision and IOL decentration<sup>13</sup>

TECNIS® IOLs is not associated with glistenings<sup>14</sup>

TECNIS Eyhance™ IOLs deliver surgeon-identified features to address the patients' visual needs

# TECNIS Eyhance™ IOLs represent the latest innovation in monofocal IOL technology

TECNIS Eyhance™ IOLs deliver **30% improvement in image contrast** at 5 mm compared to AcrySof IQ® SN60WF\*\*<sup>15</sup>



The higher the modulation transfer function (MTF) value, the more contrast is transferred to the image, resulting in higher image quality

Abbreviations: cpmm = cycles per mm; MTF = modulation transfer function

\* Assessed using modulation transfer function at 5 mm pupil size.

## Improved image contrast may increase contrast sensitivity<sup>16</sup>

**Image contrast** is the threshold luminance transferred to the image  
**Contrast sensitivity** is the measured difference in brightness levels of a viewed image



Literature reports that improved **contrast sensitivity** and better night vision **improve drivers' safety**<sup>17</sup>



Literature reports that **increased contrast** improves stair navigation and likely **decreases risk of tripping**<sup>18</sup>



Literature reports that **contrast sensitivity** **influences color perception**<sup>19</sup>

Contrast sensitivity was not measured in patients implanted with TECNIS Eyhance™ IOLs.

TECNIS Eyhance™ IOLs and TECNIS Eyhance™ Toric II IOLs provide value to your patients

# References and Important Safety Information

## References:

1. Market Scope (2019) 2019 Cataract surgical equipment market report.
2. Market Scope (2020) 2020 IOL Market Report.
3. Kauh C, Blachley T, Lichter P, Lee P, Stein J (2016) Geographic Variation in the Rate and Timing of Cataract Surgery Among US Communities. JAMA Ophthalmol 134: 267-276.
4. Bureau of Labor Statistics U.S. Department of Labor (2020) American Time Use Survey – 2019 results. USDL-20-1275 Available: <https://www.bls.gov/news.release/atus.nr0.htm> Accessed: November 11, 2020.
5. Johnson & Johnson Vision (2020) DOF2021CT4005.
6. Johnson & Johnson Vision (2020) TECNIS Eyhance™ IOL with TECNIS Simplicity™ Delivery System. Directions for Use. Document no. Z311506 Rev. A. Revision Date: 12/2020.
7. Johnson & Johnson Vision (2021) DOF2021CT4006.
8. Alarcon A, Canovas C, Koopman B, Weeber H, Auffarth GU et al. (2020) Enhancing the Intermediate Vision of Monofocal Intraocular Lenses Using a Higher Order Aspheric Optic. J Refract Surg 36 (8): 520-527.
9. Alarcon A, Canovas C, Rosen R, Weeber H, Tsai L et al. (2016) Preclinical metrics to predict through-focus visual acuity for pseudophakic patients. Biomed Opt Express 7 (5): 1877-1888.
10. Market Scope (2020) 2020 Annual sponsored US cataract surgeon survey report.
11. Piers P, Manzanera S, Prieto P, Gorceix N, Artal P (2007) Use of adaptive optics to determine the optimal ocular spherical aberration. J Cataract Refract Surg 33: 1721-1726
12. Data On File (2018) Johnson & Johnson Surgical Vision, Inc. DOF2018CT4007
13. Kahraman G, Ferdinaro C, Wetzel B, Bernhart C, Prager F, Amon M (2017) Intraindividual comparison of capsule behavior of 2 acrylic hydrophobic IOL during 5-year follow up. J Cataract Refract Surg. 43:228-233.
14. Data on File (2013) Johnson & Johnson Surgical Vision, Inc. REF2014OTH0002
15. Data on File (2021) Johnson & Johnson Surgical Vision, Inc. DOF2021CT4002
16. Kershner R (2003) Retinal image contrast and functional visual performance with aspheric, silicone, and acrylic intraocular lenses. J Cataract Refract Surg 29:1684-1694.
17. American Academy of Ophthalmology (2019) Another Reason to Get Cataract Surgery: It can Make you 48 Percent Safer on the Road. Available: <https://www.aao.org/newsroom/news-releases/detail/another-reason-to-get-cataract-surgery-safety> Accessed: November 11, 2020.
18. Jacobs J (2016) A review of stairway falls and stair negotiation: Lessons learned and future needs to reduce injury. Gait & Posture 49:159-167.
19. Annadanam A, Zhao J, Wang J, Eghrari A (2017) Effects of contrast Sensitivity on Colour Vision Testing. Neuro-Ophthalmol 41:182-186.

## INDICATIONS and IMPORTANT SAFETY INFORMATION

**Rx Only. INDICATIONS FOR USE:** The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Eyhance™ IOL for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed by extracapsular cataract extraction. The lens is intended to be placed in the capsular bag. The TECNIS Simplicity® Delivery System is used to fold and assist in inserting the TECNIS Eyhance™ Toric II IOLs for the visual correction of aphakia and pre-existing corneal astigmatism of one diopter or greater in adult patients with or without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire reduction in residual refractive cylinder. The lens is intended to be placed in the capsular bag. **WARNINGS:** Physicians considering lens implantation should weigh the potential risk/benefit ratio for any conditions described in the Directions for Use that could increase complications or impact patient outcomes. The lens should be placed entirely in the capsular bag. Do not place the lens in the ciliary sulcus. Do not attempt to disassemble, modify or alter the delivery system or any of its components, as this can significantly affect the function and/or structural integrity of the design. Do not implant the lens if the rod tip does not advance the lens or if it is jammed in the delivery system. The lens and delivery system should be discarded if the lens has been folded within the cartridge for more than 10 minutes. **PRECAUTIONS:** The safety and effectiveness of the TECNIS Eyhance™ IOL has not been substantiated in clinical trials and the effects of the optical design on quality of vision, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have not been evaluated clinically. This is a single use device, do not resterilize the lens or the delivery system. Do not store the device in direct sunlight or at a temperature under 5°C (41°F) or over 35°C (95°F). Do not autoclave the delivery system. Do not advance the lens unless ready for lens implantation. The contents are sterile unless the package is opened or damaged. The recommended temperature for implanting the lens is at least 17°C (63°F). The use of balanced salt solution (BSS) or viscoelastics is required when using the delivery system. Do not use if the delivery system has been dropped or if any part was inadvertently struck while outside the shipping box. **ADVERSE EVENTS:** The most frequently reported cumulative adverse event that occurred during the SENSAR 1-Piece IOL clinical trial was cystoid macular edema which occurred at a rate of 3.3%. **ATTENTION:** Reference the Directions for Use for a complete listing of Indications and Important Safety Information.